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Emerging studies indicate an association between
virus-induced impairment in type I interferon (IFN-I)
production and enhanced susceptibility to opportu-
nistic infections, which represent a major health
problem. Here, we provide in vivo evidence that lym-
phocytic choriomeningitis virus (LCMV) infection of
its natural murine host dramatically diminishes the
unique capacity of plasmacytoid dendritic cells
(pDCs) to secrete high levels of systemic IFN-I. While
both acute and persistent LCMV infections suppress
pDC IFN-I response, only the persistent virus induces
a long-lasting diversion of this innate immune path-
way. The consequent reduction in IFN-I production
serves to impair natural killer cell responses in
LCMV-infected mice challenged subsequently with
murine cytomegalovirus (MCMV) as an opportunistic
pathogen. This innate defect also compromises the
host’s ability to counteract early MCMV spread.
These findings provide a mechanistic explanation
for the occurrence of opportunistic infections follow-
ing viral insults and have important implications for
treating such medical complications.
INTRODUCTION
Virus infections are often associated with a transient or long-
lasting generalized suppression of the host immune response.
Dramatic examples of the global impact of virus-induced immu-
nosuppression are the 40 million individuals infected worldwide
with human immunodeficiency virus type-1 (HIV-1) with more
than 3 million deaths per year, mainly as a result of opportunistic
secondary infections (Mathers and Loncar, 2006). Similarly,
measles virus (MV) that currently infects over 30 million individ-
uals worldwide leads to approximately 500,000 deaths annually
also primarily as a consequence of secondary infections (Griffin,
1995; Guilbert, 2003). Both of these infections illustrate the clin-
ical relevance of virus-induced immunosuppression and the im-374 Cell Host & Microbe 4, 374–386, October 16, 2008 ª2008 Elsevportance of a healthy immune system to ward off infections with
opportunistic pathogens. In addition to the well-established con-
tribution of altered adaptive immunity to viral-induced immuno-
suppression (Chisari and Ferrari, 1995; Klenerman and Hill,
2005; Oldstone, 2006; Shoukry et al., 2004; Wherry and Ahmed,
2004), in vitro and epidemiological evidences indicate an associ-
ation between defective production of type I interferons (IFN-I)
and more frequent opportunistic infections (Hosmalin and
Lebon, 2006; Schlender et al., 2005; Siegal, 2003; Siegal et al.,
2001).
IFN-I orchestrate numerous biological and cellular processes
and are a critical link between innate and adaptive immunity
(Garcia-Sastre and Biron, 2006; Le Bon and Tough, 2002). Al-
though any cell can potentially produce IFN-I upon virus infec-
tion, plasmacytoid DCs (pDCs), also known as IFN-producing
cells, are a unique cell type specialized to rapidly produce prodi-
gious amount of these innate mediators following infection by
multiple viruses (Asselin-Paturel and Trinchieri, 2005; Colonna
et al., 2004; Kadowaki and Liu, 2002; Le Bon and Tough, 2002;
Liu, 2005; McKenna et al., 2005). Indeed, pDCs dedicate 50%
of their transcription to make IFN-I mRNA and following viral
stimulation synthesize a significantly broad range of these
closely related cytokines including IFN-a, IFN-b, IFN-u, IFN-l,
and IFN-t, in some cases without requiring viral replication
(Lee et al., 2007; Liu, 2005). Through the secretion of such impor-
tant innate factors, pDCs orchestrate a systemic antiviral state
programmed to directly control viral growth and communicate
danger signals to other innate cells such as natural killer (NK)
cells (McKenna et al., 2005). To accomplish this key role, pDCs
use the Toll-like receptor (TLR) system (Kato et al., 2006), includ-
ing TLR-7 (Diebold et al., 2004; Heil et al., 2004; Lund et al., 2004)
and TLR-9 (Bauer et al., 2001; Jarrossay et al., 2001; Kadowaki
et al., 2001; Krug et al., 2001; Lund et al., 2003), which rapidly
trigger IFN-I transcription through aMyD88-dependent signaling
pathway. TLR-9 mediates recognition of CpG-rich regions in the
genome of DNA viruses and bacteria including herpes simplex
virus 1 and 2, murine cytomegalovirus (MCMV) (Delale et al.,
2005), and mycobaterium tuberculosis (Bafica et al., 2005).
TLR-9 also senses malaria pigment hemozoin, extending its
role to host defense against parasite infections (Coban et al.,
2005). On the other hand, TLR-7 recognizes single strandedier Inc.
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virus (VSV) through the binding of uridine and guanosine rich se-
quences (Diebold et al., 2004; Heil et al., 2004; Lund et al., 2004).
pDCs produce most of the IFN-a protein within the first 24 hr fol-
lowing viral stimulation and then differentiate into mature DCs
with enhanced antigen presenting capacity (Liu, 2005). In vitro
studies indicated that after the first wave of IFN-I production,
pDCs are refractory upon secondary stimulations to produce
these cytokines (Jarrossay et al., 2001). However, how these
observations translate into an in vivo acute and persistent viral
infection in terms of systemic IFN-I production, innate response,
and susceptibility to secondary opportunistic infections is
unclear.
In the present report we use lymphocytic choriomeningitis vi-
rus (LCMV) infection in its natural host, the mouse, to investigate
the ability of pDCs from acutely or persistently infected hosts to
produce systemic IFN-I during in vivo challenge with TLR li-
gands. We examine how this response is associated with pDC
numbers and functional status. Finally, we evaluate the biologi-
cal significance of virus-altered pDC-IFN-I production in the con-
text of opportunistic infections in terms of systemic IFN-I levels,
activation and function of NK cells, and early innate control of the
secondary pathogen.
RESULTS
Rapid Silencing of Systemic IFN-I Production during
Both Acute and Persistent Viral Infections
To gain insight on systemic IFN-I regulation during acute and
persistent viral infections, we analyzed sera IFN-I levels through-
out the course of LCMV infection. LCMV Armstrong 53b (ARM)
and Clone 13 (Cl 13) isolates were used to model in vivo acute
and persistent infection, respectively (Ahmed et al., 1984), and
the levels of IFN-I were determined in sera (Figure 1A, left
axis). ARM and Cl 13-infected mice exhibited comparable kinet-
ics of systemic IFN-I in sera, which peaked at day 1 after inocu-
lation. By 5 days postinfection (pi), systemic levels of IFN-I
returned to baseline and remained undetectable throughout
the course of the infection regardless of whether viral clearance
(ARM) or persistence (Cl 13) occurred. These data indicate that
even in the presence of persistent Cl 13 replication of 1 3 104
to 1 3 106 PFU/ml in blood and several tissues (Ahmed et al.,
1984; Moskophidis and Zinkernagel, 1995), the initial wave of
systemic IFN-I is silenced. This observation suggested that
LCMV infection was deregulating innate immunity and raised
the dual issue of the host ability to reinduce IFN-I systemically
at latter times, and what the biological impact of IFN-I silencing
would be upon subsequent stimulations or infections.
Differential Deregulation of TLR-Induced IFN-I
Production during LCMV Infection
TLRs are well-characterized pattern recognition receptors that
induce IFN-I in response to microbial stimulation (Akira, 2006;
Beutler et al., 2006; Janeway and Medzhitov, 2002). We investi-
gated whether acute and/or persistent LCMV infection impacted
the ability of the host to increase systemic IFN-I levels in re-
sponse to TLR challenges. We focused on TLR-9 and TLR-4
stimulation as representative MyD88-dependent and -indepen-
dent pathways of IFN-I induction, respectively (Akira, 2006;Cell HoO’Neill, 2006). Uninfected and ARM (acute) and Cl 13 (persistent)
-infected mice at day 5 and 30 pi were injected with CpG-ODN
(TLR-9 ligand) or lypopolysaccharide (LPS, TLR-4 ligand). The
levels of IFN-I were determined in sera by luciferase bioassay
(Jiang et al., 2005) (Figures 1B and 1D). As previously reported
(Asselin-Paturel et al., 2005) uninfected mice rapidly responded
to CpG challenge by elevating systemic IFN-I levels in sera dis-
playing a peak response at about 3.5 hr poststimulation (Fig-
ure 1B). In contrast, following inoculation of CpG at day 5 pi,
both ARM- andCl 13 -infectedmice presented a dramatic reduc-
tion in IFN-I levels when compared to uninfected controls. The in-
hibited IFN-I response was transient for ARM-infected mice but
long-term for Cl 13-infected mice since such mice still failed to
respond to CpG at 30 and 40 days pi when LCMV-ARM-infected
mice had returned to normal (Figure 1B and data not shown).
Similar results were obtained when IFN-a was quantified by
ELISA at day 5 after ARM infection (Figure 1C). Importantly, the
defective IFN-I production during LCMV infection was not due
to an enhanced degradation of the administered CpG or a gen-
eral failure to respond to TLR-9, since upon CpG injection
LCMV-infected mice produced higher levels of IFN-g compared
to uninfected controls and succumbed to death within 24 and
48 hr after TLR-9 stimulation (Figure S1 and data not shown).
As reported before, minimal amounts of IFN-I were detected in
uninfected mouse sera after in vivo administration of LPS (Asse-
lin-Paturel et al., 2005) (Figure 1D). In sharp contrast to the TLR-9
response, IFN-I was overproduced in response to LPS inmice in-
fectedwith ARMat day 5 pi andCl 13 at day 5 and 30 pi, inducing
lethality between 6.5 and 24 hr after stimulation (Figure 1D and
data not shown). These results were confirmed by quantification
of IFN-a by Elisa at day 5 after ARM infection (Figure 1E). Finally,
we tested the ability of uninfected and ARM-infected mice to en-
hance systemic IFN-I upon stimulation with the TLR-3 ligand pol-
yribocytidylic acid, (poly[I:C], Figure S2). We found profound
reduction in TLR3-induced IFN-I levels in LCMV-infected mice
compared to uninfected controls.
Altogether, these data indicate that during in vivo virus infec-
tion, the ability of the innate immune system to produce IFN-I
upon discrete TLR stimulations can be differentially modulated.
Specifically during LCMV infection, TLR-9 and TLR-3 IFN-I
responses are abrogated while TLR-4 signaling is enhanced.
Moreover, while acute and persistent LCMV infection deregulate
TLR-IFN-I response, only the persistent infection induces a long-
lasting diversion of these innate pathways.
Quantitative and Qualitative Defects of pDCs during
Acute and Persistent LCMV Infection
pDCs are responsible for the production of IFN-I upon CpG-ODN
administration (Asselin-Paturel et al., 2005). We next investi-
gated whether the affected TLR-9 IFN-I secretion during in vivo
LCMV infection was due to a quantitative or qualitative defect
on pDCs, or both. To address this question, we first assessed
the percentage and numbers of pDCs in spleens from uninfected
and ARM- and Cl 13-infected mice at day 5 and 30 pi (Figures 2A
and 2B, respectively). Both ARM and Cl 13 infection induced
a significant reduction in pDC percentages and numbers at
day 5 pi. However, by day 30 pi pDCs showed complete recov-
ery in ARM infected mice, but Cl 13-infected mice still exhibited
a decreased number of these cells. Earlier we reported a reducedst & Microbe 4, 374–386, October 16, 2008 ª2008 Elsevier Inc. 375
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(A–E) Mice were infected with ARM or Cl 13 LCMV. Eye-bleed samples were collected before infection (day 0) and at 1, 3, 5, 30, and 40 days p.i. IFN-I activity was
measured by luciferase bioassay (left y axis) and LCMV titer by plaque assay (right y axis). Uninfected ARM- and Cl 13-infected mice at day 5 or 30 p.i. were
injected with CpG (B-C) or LPS (D-E). Blood samples were collected before injection (0 hr) and at 3.5, 6.5, and 12 hr poststimulation. IFN-I activity was measured
by luciferase bioassay and the fold of increase respect to levels at 0 hr is shown (B and D). ELISA was used to quantify IFN-a in samples collected at 3.5 hr after
stimulation fromday 5 ARM-infectedmice (C and E). Themean ±SDobtainedwith three to fourmice per group is shown (*LCMV-infected compared to uninfected
group p < 0.01). Data are representative of two to eight independent experiments.number of pDCs in the bone marrow of LCMV infected mice
(Zuniga et al., 2004). These data indicate that LCMV infection af-
fects the availability of pDCs in primary and secondary lymphoid
organs and suggest that this likely contributes to the suppressed
production of IFN-I observed in vivo. However, the altered pDC
numbers did not completely account for the profound suppres-
sion of IFN-I production in LCMV-infected mice upon in vivo
CpG challenge. At day 30 pi pDCs were only 50% reduced
while CpG-induced IFN-I levels in Cl 13-infected mice were al-
most undetectable. This led to the next series of studies to exam-
ine the functional capacity of the remaining pDCs to produce
IFN-I upon CpG stimulation. pDCs from uninfected or ARM- or376 Cell Host & Microbe 4, 374–386, October 16, 2008 ª2008 ElseviCl 13-infected mice were purified at day 5 and 30 pi and cultured
in the absence or in the presence of two different CpG se-
quences that normally induce significant IFN-I production by
mouse pDCs (Asselin-Paturel et al., 2005; Boonstra et al.,
2003; Gilliet et al., 2002; Figures 2C and 2D). In accordance
with the in vivo data, production of IFN-I in response to CpG-
ODNs was significantly impaired in pDCs from day 5 ARM-
and Cl 13-infected mice as compared to uninfected controls
(Figure 2C). At day 30 pi only pDCs from Cl 13-infected mice dis-
played lower IFN-I production in response to CpG challenge
(Figure 2D), indicating a long-lasting pDC intrinsic defect during
persistent LCMV infection. Remarkably, pDCs from ARM- and Cler Inc.
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pDC IFN-I Inhibition during Viral InfectionFigure 2. Quantitative and Qualitative pDC Alterations during LCMV Infection
(A and B) Spleen cells were obtained from uninfected (day 0), ARM and Cl 13 infected mice (day 5 and 30 p.i.). Cells were stained with the indicated markers, and
analyzed by FACS (A). The numbers indicate the mean ± SD percentage of pDCs within total spleen cells obtained with four mice per group. In (B), the absolute
number of pDCswas calculated by the total number of splenocytes and the percentage of pDCs (* LCMV-infected compared to uninfected [day 0] group p < 0.01).
(C and D) Cells were processed for FACS purification of pDCs from pools of three to four mice per group at day 5 (C) or 30 (D) p.i. and cultured with medium alone
(none), CpG-1668 (CPG-1; 1 mM), or CpG-2 (1 mM). Levels of IFN-I were measured in the supernatants at 12–15 hr postculture by luciferase bioassay. Data are
representative of two additional independent experiments.13-infected mice also failed to produce IFN-I upon TLR-7 stimu-
lation at day 5 pi and continued to be suppressed for 30 days af-
ter Cl 13, but not ARM, infection (Figure S3). To further investi-
gate the pDC functional status during LCMV infection, we
analyzed the ability of pDCs to respond to TLR signaling by pro-
ducing TNF-a, IL-12, RANTES, monocyte chemoattractant pro-
tein 1 (MCP-1), macrophage inflammatory protein 1a (MIP-1a)
and expressing MHC class II and B7-2 molecules (Figure 3).
Strikingly, the production of the aforementioned cytokines and
chemokines were not impeded by LCMV ARM or Cl 13 infection.
The expression of MHC class II molecule was also comparable
among pDCs from uninfected and LCMV-infected mice upon
CPG stimulation while B7-2 expression was upregulated in
pDCs from infected mice. Importantly, the levels of IFN-I in the
same cell culture supernatant were dramatically reduced, con-
sistently with the results described in Figure 2C. These data indi-
cate that LCMV infection selectively alters the most unique func-
tion of pDCs without affecting their more redundant functional
properties.Cell HoIn Toto, these results indicate that both acute and persistent
in vivo LCMV infection disable a fundamental pillar of immunity
not only by dampening the amount of pDCs available for innate
response but also interfering with their unique capacity to mas-
sively produce IFN-I upon TLR stimulation.
IFN-IR, IL-10, IFN-g, TNF-a, and T Cells Are Dispensable
for TLR9-IFN-I Impairment during LCMV Infection
Since the inhibition of TLR IFN-I production by pDCs occurs to
similar extends during ARM (minimal DC infection) and Cl 13 (ro-
bust replication in DCs) infections, it is likely that this alteration is
at least in part consequence of pDC exposure to the infectious
environment. In a search for a factor responsible for TLR-
9-IFN-I inhibition during LCMV infection, we analyzed the partic-
ipation of elements with demonstrated ability to suppress IFN-I
production and or pDC responses (Duramad et al., 2003; Fallar-
ino et al., 2005; Gary-Gouy et al., 2002; Palucka et al., 2005).
For that, we injected CPG in IFN-I receptor (R) knockout (ko),
IL-10 ko, IFN-g ko, TNF-a ko, and T cell-deficient TCR kost & Microbe 4, 374–386, October 16, 2008 ª2008 Elsevier Inc. 377
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(A) Spleen pDCs (53 105 cells/ml) were FACS purified from uninfected (n = 3, white bars), ARM (n = 10, striped bars), or Cl 13 (n = 10, black bars) infected mice at
day 5 p.i. Cells were cultured with medium alone (none) or CpG-1668 during 15 hr. IFN-I activity was measured in the supernatant by luciferase bioassay; other
cytokines and chemokines indicated were determined by multi-plex ELISA.
(B and C) CPG-stimulated pDCs were stained with anti-IAb and anti-B7-2 mAbs and analyzed by FACS. In (B), histrograms depict expression of the indicated
molecules; thin line, unstained control. In (C), mean fluorescence intensity (MFI) for each molecule is shown.mice infected with ARM and compared their systemic IFN-I re-
sponse to WT-infected and -uninfected controls (Figures 4A–
4E, respectively). We found similar degree of IFN-I suppression
in the aforementioned ko infected mice compared to their WT
counterparts, indicating that neither IFN-I negative feedback,
IL-10, IFN-g, TNF-a, T cells, or T cell-derived factors are essen-
tial for inhibition of TLR9-IFN-I production during ARM infec-
tion. We also investigated the participation of IFN-I and IL-10
in systemic IFN-I suppression upon CPG stimulation during
the chronic phase of Cl 13 infection by using IFN-IR ko mice
or by administering anti-IL10R mAb at day 20 pi. Again, both
of these settings showed no restoration of IFN-I production
(data not shown).
Although the molecular factors underlying IFN-I suppression
during LCMV infection are yet to be identified, these data
illuminate the complexity and uniqueness of TLR-IFN-I inhibi-378 Cell Host & Microbe 4, 374–386, October 16, 2008 ª2008 Elsevtion during viral infection and pose a challenge for future in-
vestigations.
Defective IFN-I Response during Secondary Infections
with Unrelated Pathogens
TLR-9 plays a critical role for host defense against multiple mi-
crobes including DNA viruses and mycobacteria (Bafica et al.,
2005; Coban et al., 2005; Delale et al., 2005; Krug et al., 2004;
Tabeta et al., 2004). Thus, the impact of the long-term inhibition
of TLR-9 IFN-I production during Cl 13 infection on the innate re-
sponse to an opportunistic pathogen was evaluated. We used
murine cytomegalovirus (MCMV) as a model opportunistic infec-
tion since initial IFN-I production 36 hr after MCMV infection is
known to be pDC-TLR-9 dependent (Asselin-Paturel et al.,
2001; Delale et al., 2005; Krug et al., 2004; Tabeta et al., 2004).
Uninfected or day 30-LCMV-Cl 13 infected mice were givenier Inc.
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pDC IFN-I Inhibition during Viral InfectionFigure 4. IFN-IR, IL-10, IFN-g, TNF-a, and T Cells Are Dispensable for TLR-9 IFN-I Inhibition
(A–E) IFN-IR ko (A), IL-10 ko (B), IFN-g ko (C), TNF-a ko (D), and TCR ko (E) mice at day 5 after ARM infection were injected with CPG. Uninfected and ARM-
infected WT mice were processed in parallel as controls. Blood samples were collected at the indicated time points. Elisa was used to quantify IFN-a levels
(A and B). IFN-I activity was measured by luciferase bioassay, and fold of increase respect to levels at 0 hr is shown (C–E). The mean ± SD obtained with three
to four mice per group is shown (*LCMV-infected compared to uninfected group p < 0.01).MCMV and systemic levels of IFN-I determined (Figure 5A). As
anticipated (Orange and Biron, 1996), control mice that received
a primary infection with MCMV triggered a robust IFN-I secretion
in sera as compared to uninfected mice. In contrast, a profound
reduction of IFN-I was observed in Cl 13-infected mice receiving
MCMV. Next, IFN-I production by splenic pDCs from controls or
Cl 13-infected mice challenged with MCMV was determined
(Figure 5B). While, pDCs from control MCMV-infected mice pro-
duced high levels of IFN-I, their counterparts from Cl 13-MCMV
coinfected mice failed to enhance IFN-I levels. These findings in-
dicate that LCMV infection disrupts pDC IFN-I secretion in
response to in vivo MCMV challenge. To further examine the ex-
tend of IFN-I alteration during chronic LCMV infection, we tested
IFN-I production in Cl 13-infectedmice upon secondary infection
with VSV (Figure 5C). We found that mice with a progressing Cl
13 infection also failed to elicit systemic IFN-I levels upon VSV
secondary infection. This is consistent with the previously re-
ported TLR-7-dependent IFN-I response during VSV infection
(Lund et al., 2003) and the impaired TLR-7 IFN-I production by
pDCs that we described in Figure S3. We also investigated
whether primary infection with MCMV compromises systemic
IFN-I production upon LCMV secondary infection. We observed
that an ongoing MCMV infection reduces systemic IFN-I re-
sponse upon a subsequent infection with LCMV Cl 13 (Fig-
ure 5D). These data support the idea that pDC-IFN-I inhibitionCell Hois a general event during primary viral infections that prevents
the systemic IFN-I elevation upon exposure to distinct opportu-
nistic pathogens.
Impaired NK Cell Response in LCMV-Infected Mice
upon Secondary MCMV Exposure
It has been demonstrated that during MCMV infection, produc-
tion of IFN-I by pDCs is vital for NK cell activation and function
(Dalod et al., 2003; Delale et al., 2005; Krug et al., 2004; Tabeta
et al., 2004). Therefore, we evaluated theNK cell response during
persistent LCMV infection upon MCMV superinfection. We first
determined the expression of the activation marker CD69 on
NK cells from control or Cl 13-infected mice after MCMV infec-
tion (Figures 6A and 6B). Control mice showed both a higher per-
centage of CD69+NK1.1+CD3 cells (Figure 6A) as well as an
enhanced expression of CD69 (Figure 6B). Moreover, a signifi-
cantly lower percentage of activated NK cells (Figure 6A) and
a limited upregulation of CD69 upon MCMV infection was
observed in Cl 13-MCMV dually infected mice compared to
control-MCMV infected mice (Figure 6B, black bars). To investi-
gate NK cell functions during MCMV infection, IFN-g production
and cytotoxicity by NK1.1+CD3 NK cells from control or Cl 13
infected was evaluated (Figures 6C and 6D, respectively).
Results indicated a significant reduction in both IFN-g produc-
tion and cytotoxic capacity of NK cells obtained from Clst & Microbe 4, 374–386, October 16, 2008 ª2008 Elsevier Inc. 379
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(A–D) Uninfected and LCMV Cl 13-infected mice (day 20–30 p.i.) were injected with MCMV (A and B) or with VSV (C). In (D), uninfected or MCMV-infected mice
(day 2.5 p.i.) were infected with LCMV Cl 13. In(A), (C), and (D), blood samples were collected at the indicated times after secondary infection (indicated on graph
title) and IFN-I activity was measured by luciferase bioassay. The mean obtained from six mice per group is shown (*dual viral infection compared to single viral
infection p < 0.01). Results are representative from one or two independent experiments. In (B), FACS-purified spleen pDCswere pooled from four mice per group
and cultured with medium alone. Levels of IFN-I were measured in the supernatants at 15 hr postculture. Results are representative of three independent exper-
iments.13-MCMV-coinfected mice compared to control MCMV-in-
fectedmice. Interestingly, NK cell dysfunctionwas accompanied
with a significant reduction in systemic IFN-g levels after MCMV
infection of Cl 13-infected mice compared to MCMV-infected
controls (Figure 6E).
In concert, these results indicate that the long-term inhibition
of TLR-9-IFN-I production during Cl 13 infection relates to im-
paired pDCs and NK cell innate responses upon subsequent en-
counter with an unrelated opportunistic pathogen.
Control of Early MCMV Replication Is Compromised
in LCMV-Infected Mice
Early activation of pDCs and NK cells is decisive for counteract-
ing MCMV spread (Dalod et al., 2003; Degli-Esposti and Smyth,
2005). The next set of experiments investigates the biological im-
pact of LCMV diversion of innate response on the containment of
MCMV infection (Figure 7A). Control mice that received a primary
infection with MCMV had less than 50 PFU/ml of MCMV by 4
days pi. In contrast, 3–4 log of infectious MCMV was detected
in Cl 13-MCMV-coinfected mice. These results were further sup-
ported by real time PCR amplification of MCMV early inducible
gene (Ie-1) (Figure 7B), showing a significantly higher expression
in MCMV-Cl 13-infected mice compared to controls.
Different mechanisms are responsible in C57BL/6 mice for re-
sistance against MCMV in the spleen (mostly NK cells) and in the
liver (mainly IFN-g). Therefore, we analyzed in parallel MCMV ti-380 Cell Host & Microbe 4, 374–386, October 16, 2008 ª2008 Elseviters in spleens and livers (Figure 7C). The results indicate that
while Cl 13-infected mice that received MCMV as a secondary
infection exhibit 2 log higher MCMV titers in the spleen than
controls, no significant differences could be detected in the liver.
Considering the reduced IFN-g levels detected in the serum of
LCMV-MCMV- coinfected mice (Figure 6E), it is likely that local
secretion of IFN-g in the liver would compensate for its systemic
deficit. We also investigated whether the failure to control MCMV
secondary infection occurs during a primary acute infection with
ARM, within the time window of altered pDC response
(Figure 7D). As expected, the spleen MCMV titers were signifi-
cantly elevated in LCMV-ARM-MCMV dual-infected mice com-
pared to single MCMV-infected mice, but again, no increase
could be appreciated in liver.
Finally, we evaluated early viral containment using different
combinations of primary and secondary pathogens. We found
that both control and Cl 13-infected mice that received VSV as
primary and secondary infections, respectively, were able to
completely eradicate the virus by day 4 pi (data not shown). Sim-
ilarly, no differences in LCMV replication were detected when Cl
13 was used as a secondary pathogen to challenge mice with
a progressing MCMV infection (Figure 7E).
These data indicate that the deleterious effect of LCMV infec-
tion on innate immune response(s) contributes to disarming the
host capacity to contain early replication of an extraneous path-
ogen such as MCMV. However, the results obtained with VSVer Inc.
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(A and B) Uninfected and Cl 13 infected mice (day 30 pi) were infected with MCMV. Spleen cells were stained with anti NK1.1, anti-CD3, and anti-CD69mAb, and
the levels of CD69 on NK1.1+CD3 cells determined by FACS. Histograms depicting CD69 expression are shown in (A) and MFI is shown in (B). (*Cl 13-MCMV
coinfected compared to control-MCMV group p < 0.01). Results are representative of two independent experiments.
(C and D) FACS-purified spleen NK1.1+CD3 cells were pooled from three mice per group and cultured with medium alone. After 15 hr, levels of IFN-g were
measured in the supernatants (C) and cells were cultured with 51Cr-labeled YAC-1 targets in a cytotoxicity assay (D). Results are representative of two to four
independent experiments.
(E) Blood samples were collected at indicated times post MCMV infection, and IFN-g activity was measured by ELISA. Mean ± SD from three mice per group is
shown. (*Cl 13-MCMV coinfected compared to control-MCMV group p < 0.05). Results are representative of two independent experiments.and LCMV secondary infections emphasize that the biological
impact that IFN-I inhibition has on the early control of an oppor-
tunistic pathogen depends on the unique nature (i.e., viral prop-
erties, dose, route) of the secondary infection.
DISCUSSION
In vitro and epidemiological data support an association between
increased incidence of opportunistic infections during HIV or MV
infections and the inability of infected cells to produce IFN-I (Hos-
malin and Lebon, 2006; Schlender et al., 2005; Siegal, 2001,
2003). This report provides an explanation on how this impaired
production of IFN-I contributes to pathogenesis in vivo. Compel-
ling evidence show that in vivo infectionwith LCMV interfereswith
the unique ability of pDCs to secrete prodigious amount of IFN-I
uponTLRstimulation. This innate immunedeficiency is sustained
over a longperiodduring apersistent infectionand is adirect con-
sequence of quantitative and qualitative alterations on pDCs.
Furthermore, this virally induced immune defect is biologically
meaningful in preventing an effective innate response (i.e., sys-
temic IFN-I production and NK cell function) by the host upon en-
counteringanopportunisticpathogen, suchasMCMV,and relates
to early spread and delayed clearance of the secondary infection.
Like other viruses, LCMV induces enhanced systemic IFN-I
early after infection (Biron, 1998). At present the cellular source
of the early wave of systemic IFN-I during LCMV infection is un-
clear. Although pDCs secrete IFN-I during LCMV infection (JungCell Hoet al., 2008; Montoya et al., 2005), the early peak of systemic
IFN-I was still detected in the absence of pDCs (Louten et al.,
2006). Importantly, systemic IFN-I is rapidly silenced during
both acute and chronic LCMV infection, indicating that the pro-
duction and presence of high viral load in blood and several tis-
sues (Ahmed et al., 1984; Moskophidis and Zinkernagel, 1995) is
not sufficient to maintain enhanced levels of IFN-I in serum. The
inhibition of systemic IFN-I early after LCMV infection is in sharp
contrast to the local IFN-I production by spleen and bone mar-
row DCs that support chronic infection by Cl 13 and manifest
a sustained production of IFN-I for at least 50 days p.i. (Diebold
et al., 2004; Hahm et al., 2005). Thus, it is possible that LCMV has
evolved selective strategies to block systemic IFN-I response
and/or that the host is armed with immune-regulatory mecha-
nisms to prevent sustained-systemic IFN-I production that could
lead to immunopathology. Moreover, TLR-9 and TLR-3-IFN-I re-
sponsesaredramatically abrogatedduring LCMV infectionwhile,
in contrast, TLR-4 signaling is enhanced. These observations
demonstrate that an ongoing natural viral infection can differen-
tiallymodulate the ability of the innate immune system toproduce
IFN-I upon in vivo TLR stimulation, specifically suppressing se-
lective pathways while re-enforcing others. This differential de-
regulation may be applicable to other viral infections that, as
LCMV (Doughty et al., 2001; Durbin et al., 2003; Nguyen and
Biron, 1999), induce an enhanced response to LPS and/or sus-
ceptibility to endotoxic shock (Baqui et al., 2000; Bender et al.,
1993; Fejer et al., 2005; Nansen and Randrup Thomsen, 2001).st & Microbe 4, 374–386, October 16, 2008 ª2008 Elsevier Inc. 381
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pDC IFN-I Inhibition during Viral InfectionFigure 7. Secondary Virus Replication in Spleen and Liver
(A–E) Mice uninfected, infected with LCMV Cl 13 at day 18 to 40 p.i. (A, B, and C) or infected with LCMV ARM at day 5 p.i. (D) were injected with MCMV. In (E),
uninfected or MCMV-infectedmice at day 2.5 p.i. were challenged with LCMV. Spleens (A–E) and livers (C–E) were collected at day 4 post secondary infection. In
(A)–(E), titers of secondary virus were determined by plaque assay. Each symbol represents an individual mouse and dotted lines indicate the detection limit. In
(B), MCMV Ie-1 gene was determined by Q-PCR. Results are representative from two independent experiments. The mean ± SD obtained from four to six mice
per group is shown (*dual viral infection compared to single viral infection p < 0.01).LCMV infection affects pDCs at multiple levels. LCMV causes
a numeric defect in this cell population in both periphery and
bone marrow. This is likely related to the virus ability to block
DC development from early undifferentiated progenitors
(Hahm et al., 2005; Sevilla et al., 2004) and to redirect the differ-
entiation of immature bone marrow pDCs into CD11b+ cDCs
(Zuniga et al., 2004). In addition, LCMV infection alters the qual-
ity of the remaining pDCs by disabling their distinctive function
(i.e., IFN-I production) without affecting secretion of other cyto-
kines and maturation. The ability of LCMV or other viruses to se-
lectively affect a unique function in neurons, endocrine cells, or
immune cells while sparing other differentiated functions
thereby disrupting homeostasis and causing disease has been
previously reported (de la Torre et al., 1992, 1996; Oldstone,
1982, 2002). However, viral interference with IFN-I biosynthesis
has been usually associated with virus replication within the af-
fected cells, altering IFN-I induction, transcription, RNA pro-
cessing, and/or translation (Garcia-Sastre and Biron, 2006). In
particular, LCMV infection of A549 cells inhibits IRF-3 phosphor-
ylation and IFN-b synthesis (Martinez-Sobrido et al., 2006).
Strikingly, we found that at day 5 p.i., LCMV ARM suppresses
pDC-IFN-I response to a similar extent than LCMV Cl 13, al-
though the former one infects a minimal number of DCs while
the latter one strongly replicate in this cell population (Borrow
et al., 1995; Sevilla et al., 2000; data not shown). These data
suggest that virus replication within pDCs does not correlate
with IFN-I inhibition but instead the pDC exposure to the infec-
tious environment may play a major role. The pDC-IFN-I impair-
ment could result from an advanced maturation status triggered382 Cell Host & Microbe 4, 374–386, October 16, 2008 ª2008 Elsevieby the virus infection and is consistent with a previous report
demonstrating that DC exposure to herpes simplex virus
in vivo, prevent them to produce IFN-a after rechallenge with
the same virus in vitro (Bjorck, 2004).
We investigated the biological implications of the impaired
TLR-IFN-I response during LCMV infection by using MCMV as
a model of opportunistic infections. MCMV is a well-character-
ized mouse natural pathogen (Krmpotic et al., 2003), which is
recognized by pDCs through TLR-9. As a result, a massive
IFN-I response is initiated and is crucial for direct antiviral effect
and the orchestration of other innate cells, i.e., NK cells (Biron,
1999; Dalod et al., 2003; Degli-Esposti and Smyth, 2005; Delale
et al., 2005; Krug et al., 2004; Tabeta et al., 2004). We noted that
LCMV infection compromises MCMV and VSV innate responses
as indicated by the reduced levels of systemic IFN-I. Moreover,
also impaired IFN-g and defective activation and function of
pDCs and NK cells were observed during superinfection of
LCMV-infected mice with MCMV. NK cell dysfunction has
been described previously during several viral infections (Ahmad
and Alvarez, 2004; Fauci et al., 2005), and our data suggest that
their in vivo alteration could be in part a consequence of impaired
TLR-IFN-I response. It is important to mention that other innate
immune defects during Cl 13 infection, such as poor IL-12 pro-
duction upon secondary MCMV infection (Figure S4), may cou-
ple to the impaired IFN-I and NK cell responses to determine
the early MCMV spread observed. Indeed, our failure to restore
MCMV containment by the sole injection of recombinant IFN-
b during Cl 13 infection (Figure S5) suggests multifactorial events
acting in conjunction to discredit innate defense duringr Inc.
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would facilitate early microbial spread and could potentially
compromise the CD8 T cell response against secondary patho-
gens, which is suppressed during persistent Cl 13 infection
(Tishon et al., 1993). Notably, many other serious human oppor-
tunistic infections are sensed through TLR-9 (Bafica et al., 2005;
Coban et al., 2005), and inhibition of TLR-9 IFN-I response is
likely facilitating their growth in the virally infected hosts. Our
findings are in agreement with a previous report indicating that
transient IFN-I exhaustion during acute infection with Semliki
Forest virus (SFV) associates with enhanced susceptibility to
secondary infections (Alsharifi et al., 2006).
LCMV infection in its natural host, the mouse, has been a Ro-
setta Stonemodel to illuminate the occurrence and cause ofmul-
tiple host-virus interactions in vivo (Oldstone, 2006; Zinkernagel,
2002). The present study set the basis to use LCMVmodel to un-
derstand the deregulation of innate immunity during acute and
chronic viral diseases. In summary, our results indicate that inhi-
bition of systemic TLR-IFN-I production by pDCs during in vivo
viral infection interferes with efficient and effective innate im-
mune response to a subsequent infection and sets a stage for
enhanced susceptibility of the host to opportunistic pathogens.
Our data support the concept that an in vivo virus infection in ad-
dition to disordering adaptive immune response can also dis-
credit the innate immune system, thus favoring microbial spread
and evolution.
EXPERIMENTAL PROCEDURES
Viruses
The ARM53b and Cl 13 LCMV clones were grown, identified, and quantified as
described (Ahmed et al., 1984; Borrow et al., 1995; Salvato et al., 1991). Smith
strain of MCMV was obtained from Bruce Beutler, The Scripps Research Insti-
tute (TSRI). MCMV stocks were prepared from salivary glands of BALB/c mice
given 13 104 PFU intraperitoneally (i.p.) (Tabeta et al., 2004). Homogenates of
pooled salivary glands were made in sterile PBS and viral titers determined by
plaque assay as described (Orange et al., 1995). New Jersey VSV strain was
obtained fromDr. Robert Lamb (Northwestern University, IL) and viral titers de-
termined on baby hamster kidney cells after 1 hr absorption at 37C and 48 hr
of 1% agarose overlay.
Mice
C57BL/6 mice were obtained from the closed breeding colony of TSRI. IL-10
ko, TNF-a ko and IFN-g ko mice were obtained from Jackson Laboratory.
IFNR-I ko mice were obtained from Dr. Jonathan Sprent (TSRI) and TCR ko
mice were a gift from Dr. Stephen Hedrick (UCSD). All ko mice used were in
C57BL/6 background. Mice at 6–8 weeks of age were infected by i.v. inocula-
tion of LCMV (23 106 PFU either ARM or Cl 13), i.v. injection with VSV (53 107
PFU) or i.p. injection of MCMV (13 104 PFU). Where indicated LCMV Cl 13-in-
fectedmice received 13 104 units of recombinant IFN-b i.p. 1 hr beforeMCMV
infection (Research Diagnostics). For in vivo treatment with TLR ligands, mice
were injected in the tail vein with LPS (5 mg in 200 ml of PBS, Alexis), Poly(I:C)
(5 mg in 200 ml of PBS, Invivogene) or CpG-ODN (IDT, Inc.) preparations. CPG
preparations consisted of 5 mg of CpG-1668 (TCCATGACGTTCCGATGCT)
mixed with 30 ml of a cationic liposome preparation (DOTAP; F. Hoffmann-La
Roche Ltd.) and 170 ml PBS. For IL-10 signaling blockade during persistent in-
fection, day-20-Cl13 infected mice received 500 mg of anti-IL-10R mAb
(clone 1B1.3a, BD Biosciences) 8 hr before CPG injection. Mouse handling
conformed to the requirements of the National Institutes of Health guidelines
and TSRI Animal Research Committee.
Cell Purification
Spleens were removed and incubated with collagenase D (1mg/ml, Roche, In-
dianapolis, IN) for 20 min at 37C. Single-cell suspension of splenocytes wereCell Hoenriched and purified as described previously (Zuniga et al., 2004). pDCs (de-
fined as CD11c+B220+120G8highCD11bCD3CD19NK1.1) and NK cells
(defined as CD3NK1.1+) were separated using a FACS-Aria Sorter (Becton
Dickinson, San Jose, CA). Purity was > 98%.
Flow Cytometry
Antibodies used were either purchased from BD Pharmingen or eBioscience
(San Diego, CA) to stain splenocytes: CD11b-PE-CY7, anti-CD11c-APC,
anti-CD19-Percp-Cy5.5, anti-NK1.1-Percp-Cy5.5, anti-CD3- Percp-Cy5.5,
anti-B220-APC-CY7, anti-B220-FITC, anti-NK1.1-PE, anti-CD69-FITC, anti-
IAb-Alexa-700, and anti B7-2-PE. Anti-120G8 monoclonal antibody was kindly
provided byGiorgio Trinchieri and conjugated to Alexa 488 followingmanufac-
ture instructions (Molecular Probes, Invitrogen, Carlsbad, CA). Prior to staining
all cell preparations were blocked with 3.3 mg/ml anti-mouse CD16/CD32 (Fc
block, BD PharMingen) in PBS containing 1% FBS for 10 min. The Fc block
was also included in all 20 min surface stains. Cells were acquired using the
Digital LSR II flow cytometer (Becton Dickinson, San Jose, CA). Flow cytomet-
ric data were analyzed with the FlowJo software.
pDC Cultures and In Vitro Stimulation
Unless otherwise indicated, pDCs were plated at 1 3 105 cells/ml in 100 ml
RPMI complete medium (10% FBS, 2 mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin, 15 mM b-mercaptoethanol). For pDC stimulation, cells
were cultured overnight in the presence of HPLC purified CpG-1668 (TCCAT-
GACGTTCCGATGCT phosphorothioate-modified; IDT, Inc.), CpG-2 (TCA TTG
GAA AAC GTT CTT CGG GGC G phosphorothioate-modified; IDT, Inc.) at
1 mM or Loxoribine (Invivogen, San Diego, CA) at 100 mM and supernatants
then collected.
Cytokine Measurements
IFN-I activity was measured with reference to a recombinant mouse IFN-b
standard (Research Diagnostics) using a L-929 cell line transfected with an in-
terferon-sensitive luciferase obtained from Bruce Beutler, TSRI (Jiang et al.,
2005). Where indicated the amount of IFN-a production was determined by
ELISA (PBL Biomedical, Picataway, NJ). IFN-gwas quantified by ELISA (eBio-
science, San Diego, CA). TNF-a, IL-12, RANTES, MCP-1, and MIP-1 a were
quantified by multiplex ELISA (Quansys Biosciences, UT).
NK Cell IFN-g Production and Cytotoxicity
FACS-purified NK cells were cultured at 106 cells/ml for 15 hr in complete me-
dium at 37C in 5% CO2. Supernatants were harvested and stored at 70C
for IFN-g quantification by ELISA. NK cell cytotoxic activity was assessed by
51Cr release, in a 4 hr assay at 37C, from YAC-1 target cells, as described
(Orange et al., 1995).
Real-Time RT-PCR for Quantification of MCMV mRNA
Total RNA was extracted from spleen homogenates using RNeasy kit
(QIAGEN) digestedwith DNase I (RNase-free DNase Set, QIAGEN) and reverse
transcribed into cDNA. Quantification of cDNA was performed using SYBR
Green PCR Kit (Applied Byosistem) and Real-Time PCR Detection System
(ABI). The relative RNA levels of Ie-1 were normalized against cellular glyceral-
dehydes 3-phosphate dehydrogenase (GAPDH) RNA as described (Delale
et al., 2005).
Statistical Analysis
Statistical differenceswere determined by Student t test or oneway analysis of
variance (ANOVA) with InStat 3.0 software (GraphPad, CA.). p < 0.05were con-
sidered significant.
SUPPLEMENTAL DATA
Supplemental Data include five figures and can be found online at http://www.
cell.com/cellhostandmicrobe/supplemental/S1931-3128(08)00299-0.
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